Tumorigenesis is a multistep process that involves the activation of oncogenes and the inactivation of tumor suppressor genes. The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) in immortal cell lines has been well studied, while the eects of v-Abl in primary ®broblasts are less clear. Here we show that v-Abl causes cell cycle arrest in primary mouse embryonic ®broblasts (MEFs) and elevated levels of both p53 and the cyclin-dependent kinase inhibitor p21
Introduction
The v-Abl gene was originally identi®ed as the transforming gene of the Abelson murine leukemia virus (A-MuLV), a retrovirus which causes lymphosarcoma in mice (Abelson and Rabstein, 1970; Rosenberg and Witte, 1988) . The v-Abl gene is a hybrid of a portion of the viral Gag gene fused with a sequence derived from the endogenous c-Abl gene, which encodes a non-receptor tyrosine kinase (Go et al., 1980) . v-Abl has elevated tyrosine kinase activity compared with c-Abl, and cells transformed by v-Abl have higher phosphotyrosine levels on many proteins. In vitro, A-MuLV transforms several ®broblastic (Scher and Siegler, 1975) and pre-B lymphoid cell lines (Pratt et al., 1977) , whereas in vivo, the virus primarily transforms pre-B cells (Rosenberg and Witte, 1988) . In Philadelphia chromosome-positive human leukemias, Abl is activated by a chromosomal translocation which results in a chimeric gene, Bcr-Abl. v-Abl and Bcr-Abl activate many common signal transduction pathways.
Although v-Abl is a potent oncogene, expression of v-Abl itself is not sucient for transformation in most settings. Primary mouse embryonic ®broblasts (MEFs) are highly resistant to v-Abl transformation. While many cells are initially infected in vivo, v-Abl-induced pre-B cell tumors are usually clonal or oligo clonal, suggesting that rare clones grow out (Green et al., 1987 (Green et al., , 1989 . Similarly, A-MuLV infected cells passaged in vitro gradually gain higher oncogenic activity by clonal selection. Primary v-Abl transformed pre-B cells are poorly tumorigenic and prone to apoptosis soon after isolation, while surviving cells eventually become highly proliferative and tumorigenic (Thome et al., 1997; Whitlock et al., 1983) . These observations suggest that additional genetic changes are required to achieve full malignant transformation. However, the nature of the additional events which facilitate v-Abl transformation is poorly understood.
Inactivation of the p53 tumor suppressor gene might be one important step in A-MuLV-induced transformation. Over 40% of A-MuLV transformed pre-B cell clones express mutant forms of p53 (Thome et al., 1997) . Many human tumors, including a signi®cant percentage of Bcr-Abl-induced leukemia, contain p53 mutations (Ahuja et al., 1989; Imamura et al., 1994; Prokocimer and Rotter, 1994) . p53 functions as a sequence speci®c transcription factor and induces both cell cycle arrest and apoptosis. p53 is not required for normal development, but is required for preventing cell proliferation and inducing apoptosis under certain conditions, such as DNA damage, hypoxia, and other cellular stresses (reviewed in Giaccia and Kastan, 1998) . Recent studies show that oncogenic insults induce p53 activation in a p19ARF-dependent manner (reviewed in Sherr, 1998) . The Ink4a/ARF locus encodes two proteins, p16INK4a and p19ARF (Alternative Reading Frame). Overexpression of p16INK4a and p19ARF induces cell cycle arrest through distinct mechanisms. p16INK4a directly inhibits the D-type cyclin-dependent kinases, CDK4 and CDK6, while p19ARF induces the stabilization of p53. DNA damage and oncogenic insults induce p53 activation through dierent pathways. p19ARF is only required for oncogene-induced p53 activation but not for DNA damage-induced p53 activation. Mice homozygous for either p53 or p19ARF deletion develop normally, but are highly prone to cancer (Donehower et al., 1992; Kamijo et al., 1997) . The p19ARF-p53 pathway serves as a cellular defense mechanism against abnormal growth promoting signals. In immortal cell lines, this pathway is disabled, which might explain why v-Abl can transform immortal cell lines but not primary ®broblasts.
For unknown reasons, some immortal cells are resistant to v-Abl transformation. v-Abl poorly transforms Balb/c 3T3 ®broblasts; instead v-Abl exhibits à lethal' eect. This eect is associated with the Cterminal region of v-Abl: forced passaging of Balb/c cells harboring wild-type A-MuLV generated p90 AMuLV, a mutant virus harboring a C-terminal deletion which can transform Balb/c cells without exhibiting toxicity (Ziegler et al., 1981) . The nature of the v-Abl lethal' eect in Balb/c 3T3 cells is not clear, and it could result from v-Abl-induced apoptosis or cell cycle arrest. Similar ®ndings were also made in NIH3T3 cells (Go et al., 1982; Watanabe and Witte, 1983) . Later, it became clear that there are two populations in NIH3T3 cells: v-Abl transforms the permissive cells (represented by the 4A2 cell line), but causes cell cycle arrest in the non-permissive cells (represented by the 1A4 cell line) (Renshaw et al., 1992) . Interestingly, in contrast to 1A4 cells, 4A2 cells fail to induce p53 and p21
Cip in response to DNA damage , indicating a defective p53 function in 4A2 permissive cells. Furthermore, c-Abl induced cell cycle arrest requires p53 and the p53 binding region in the C-terminal part of c-Abl (Goga et al., 1995; Yuan et al., 1996) . These observations raise the possibility that p53 might hinder v-Abl transformation in immortal cell lines.
In this study, we examined the role of p53 and p19ARF in antagonizing v-Abl transformation. We found that v-Abl induced cell cycle arrest in a p53-and p19ARF-dependent manner in primary MEFs. Although wild-type MEFs were highly resistant to AMuLV transformation, p53-or p19ARF-de®cient MEFs became susceptible. We also showed that although p53 mediated v-Abl-induced cell cycle arrest in primary cells, p53 was not the major mediator of vAbl toxicity in immortal ®broblasts.
Results

v-Abl induces cell cycle arrest in a p53-and p19ARF-dependent manner in primary MEFs
We chose a well-characterized system, primary MEFs, to examine the eects of v-Abl in primary cells. The vAbl oncogene was introduced into MEFs through a replication-defective retrovirus: these retroviruses were generated by transfecting the Phoenix packaging cell line with retroviral vectors pGD-vAblPuro or pBabePuro control. The viruses were used to infect matched pairs of wild-type and p53 7/7 MEFs, and matched pairs of wild-type and p19ARF 7/7 MEFs, and infected cells were selected with puromycin. After 7 days of puromycin selection, surviving cells were examined. All wild-type MEFs transduced with the control vector pBabePuro had normal morphology, while all wildtype MEFs transduced with v-Abl became¯at and enlarged, appearing similar to cells that are losing growth capacity and becoming senescent (Figure 1 ). p53 7/7 and p19ARF 7/7 MEFs transduced by v-Abl did not exhibit this¯at and enlarged morphology.
To monitor the ability of these cells to carry out mitosis, cells were labeled with BrdU for 18 h, ®xed, and stained with anti-BrdU antibodies. Approximately 60% of wild-type MEFs transduced with pBabePuro were BrdU-positive (Figure 2) . Signi®cantly, only 10% of wild-type MEFs transduced with v-Abl were BrdUpositive, indicating that v-Abl expression induced cell cycle arrest in these cultures. In contrast, v-Abl expression did not aect the percentage of BrdUpositive cells in either p53 7/7 or p19ARF 7/7 MEFs (Figure 2 ). These results demonstrate that v-Abl induces arrest in MEFs and this arrest is dependent on p53 and p19ARF.
v-Abl elevates the protein levels of p53 and p21 in primary MEFs
To further characterize the response to v-Abl expression in these cells, the levels of expression of vAbl and cell cycle regulatory proteins were examined by immunoblotting. v-Abl was expressed at a similar level in wild-type, p53 7/7 and p19ARF
7/7
MEFs transduced by v-Abl (Figure 3 ). The levels of p53 protein were signi®cantly elevated in v-Abl-transduced wild-type MEFs (Figure 3 ). In contrast, the level of p53 in v-Abl-transduced p19ARF 7/7 MEFs remained unchanged. These results demonstrate that p19ARF is required for p53 accumulation in response to v-Abl expression. Since p21
Cip is a major downstream eector Cip was also assayed. As expected, p21
Cip expression was increased in v-Abl-transduced wildtype MEFs, but not in v-Abl-transduced p53 7/7 and p19ARF 7/7 MEFs ( Figure 3 ). Therefore, p21
Cip might be one of the major mediators responsible for v-Abl induced cell cycle arrest in primary cells.
p53 and p19ARF de®ciency promotes v-Abl transformation in MEFs
If the cell cycle arrest mediated by p53 and p19ARF is a signi®cant impediment to v-Abl transformation of MEFs, elimination of these genes by mutation should permit transformation of these normally resistant cells. We examined the transforming activity of v-Abl in wild-type, p53 7/7 or p19ARF 7/7 MEFs, using a soft agar assay. Matched pairs of wild-type and p53
7/7
MEFs, and matched pairs of wild-type and p19ARF 7/7 MEFs were infected with A-MuLV or Moloney murine leukemia helper virus (Mo-MuLV) as a control. Two days after infection, half of the cells were plated in soft agar and half of the cells were monitored for v-Abl expression. All MEFs infected with A-MuLV expressed similar levels of v-Abl protein, suggesting that these MEFs are equally susceptible to infection (data not shown). As expected, wild-type, p53
, or p19ARF
MEFs infected by Mo-MuLV did not generate any colonies in agar (Figure 4) . Consistent with the notion that primary MEFs are highly resistant to the transforming activity of A-MuLV, wild-type MEFs infected with AMuLV produced no colonies (Figure 4 ). In contrast, p53 7/7 or p19ARF 7/7 MEFs infected by A-MuLV produced many colonies (Figure 4 ). Colonies in soft agar were picked and expanded in liquid culture. These transformed cells had morphologies similar to AMuLV-transformed NIH3T3 cells, including round shape, high refractility, and low substratum adherence (data not shown). The expression of v-Abl protein in these transformed cells was con®rmed by Western blotting analysis (data not shown). These experiments showed that loss of p53 or p19ARF function rendered primary MEFs susceptible to v-Abl transformation, suggesting that the p19ARF-p53 pathway plays a crucial role in blocking the transforming activity of v-Abl.
To further establish the role of p53 de®ciency in vAbl transformation, we applied a dierent strategy. Rather than comparing wild-type and p53
7/7 MEFs, we used HPV16 E6 viral oncoprotein to disrupt normal p53 function in a wild-type background. The HPV16 E6 oncoprotein associates with p53, and promotes its ubiquitin-dependent degradation (Schener et al., 1990 (Schener et al., , 1993 . Wild-type MEFs, infected with a retrovirus expressing E6 or mock infected, were then challenged with Mo-MuLV or A-MuLV. Cells were plated in DMEM containing 0.3% agar and 20% fetal bovine serum. After 2 weeks incubation, the number of transformed colonies was counted (Table 1) . Although E6 or v-Abl alone did not transform wild-type MEFs, E6 and v-Abl together synergistically transform wildtype MEFs (Table 1 ). These data further support our conclusion that loss of p53 function is important for vAbl transformation.
v-Abl elevates the p19ARF mRNA levels
As shown previously, p19ARF is required for v-Ablinduced p53 and p21 induction. To directly examine the eect of v-Abl on p19ARF expression in wild-type cells, wild-type MEFs were repeatedly infected with high titer preparation of A-MuLV. Seventy hours after infection, the p19ARF mRNA level was determined by RNase protection. As expected, v-Abl expression substantially elevated the p19ARF mRNA level (Figure 5a ). Cip protein levels by v-Abl in primary MEFs. MEFs were infected with viruses and selected with puromycin as described in Figure 1 . Puromycin-resistant cells were lysed with RIPA buer, resolved by SDS ± PAGE, transferred to nitrocellulose and blotted with anti-Abl, anti-p53, anti-p21
Cip , or anti-actin antibodies Figure 4 Transformation of p53 7/7 or p19ARF 7/7 MEFs by v-Abl. Wild-type, p53 7/7 or p19ARF 7/7 MEFs were infected with A-MuLV or Mo-MuLV. One day after infection, cells were plated in 0.3% soft agar. Photographs were taken 2 weeks after infection If p19ARF is upstream of p53, we would predict that p19ARF would also be expressed at a higher level in v-Abl transformed p53
7/7 cells. The mRNA levels of p19ARF in two v-Abl-transformed p53 7/7 clones and parental p53 7/7 MEFs were examined by Northern blotting analysis using a DNA probe speci®c for mouse p19ARF. As expected, both v-Abl-transformed p53 7/7 cell lines expressed signi®cantly higher levels of p19ARF steady-state mRNA as compared with parental p53
MEFs (Figure 5b ). This experiment not only demonstrated that v-Abl increased p19ARF mRNA level, but also showed that the high expression of p19ARF did not inhibit v-Abl transforming activity in the absence of p53, supporting the idea that p19ARF functions upstream of p53 and that the negative eect of p19ARF on cell growth requires p53.
p53 is not responsible for the toxicity of v-Abl in immortal ®broblasts p53 might also contribute to the cytotoxicity of v-Abl, and so antagonize v-Abl transformation in the non- 7/7 cells and parental p53 7/7 MEFs were separated by electrophoresis and blotted with a DNA probe speci®c for murine p19ARF (upper panel) and GAPDH (bottom panel). Bands were quantitated by phosphorImager using GAPDH as standard. Fold induction was calculated relative to the p19ARF signal of the parental p53 7/7 MEFs Figure 6 The disruption of p53 function of 1A4 cells by HPV16 E6 protein. 1A4 and 4A2 cells were infected with pGDN virus or E6 virus and subjected to G418 selection. G418 resistant clones were treated with 1 mM MMS for 4 h. Cell lysates were blotted with anti-p21 Cip (upper panel) and anti-Actin (bottom panel) antibodies Figure 7 E6 protein fails to relieve the toxicity of v-Abl in 1A4 cells. 1A4 and 4A2 cells transduced with pGDN or E6 virus were transfected with pGD-vAblPuro or pBabePuro. Two days after transfection, cells were split and subjected to puromycin selection. After a 10 day selection, the number of drug-resistant colonies was counted. For each sample, the average of two independent experiments is represented , MMS induced p21
Cip expression in 1A4-pGDN cells but not 4A2-pGDN cells (Figure 6 ), suggesting a defective p53 pathway in 4A2 cells. As expected, MMS failed to induce p21
Cip expression in 1A4-E6 cells, indicating that the p53 function has been successfully inactivated in these cells (Figure 6 ).
To test the toxicity of v-Abl in these cells, pGDvAblPuro or pBabePuro was transfected into these cells by a calcium phosphate method. Cells were subjected to puromycin selection 2 days after transfection, and the number of drug-resistant colonies was counted after 10 days of selection. Roughly equal numbers of colonies were observed on 4A2-pGDN cells transfected with pBabePuro and 4A2-pGDN cells transfected with pGD-vAblPuro ( Figure 7 ). In contrast, tenfold fewer colonies were observed in 1A4-pGDN cells transfected with pGD-v-AblPuro as compared with 1A4-pGDN cells transfected with pBabePuro (Figure 7) , consistent with the idea that v-Abl is toxic to 1A4 cells but not 4A2 cells. Signi®cantly, v-Abl exerted a similar level of toxicity in 1A4-E6 cells, manifested by the same reduction in a number of drug-resistant colonies generated in pGDvAblPuro-transfected 1A4-E6 cells as compared with the control pBabePuro-transfected 1A4-E6 cells ( Figure  7) . The ®nding that loss of p53 function failed to relieve v-Abl toxicity in 1A4 cells suggests that p53 cannot be the major mediator of v-Abl toxicity in the non-permissive cells.
To test whether loss of p53 function rendered the non-permissive cells susceptible to v-Abl transforming activity, we challenged cells with pGD-v-Abl virus. Foci formation was examined after 2 weeks incubation (Table 2) . pGD-vAbl virus eciently transformed both 4A2-pGDN cells and 4A2-E6 cells. Apparent titers of pGD-vAbl virus on these cells were around 10 5 f.f.u./ ml. In contrast, pGD-vAbl virus failed to transform either 1A4-pGD cells or 1A4-E6 cells. The apparent titers of pGD-v-Abl virus on these cells were below 10 2 f.f.u./ml. The ®nding that loss of p53 function failed to make the non-permissive cells susceptible to vAbl transformation suggests that p53 is not the major factor determining the susceptibility of NIH3T3 cells to v-Abl transforming activity.
Discussion
A number of previous studies have suggested p53 might play an important role in inhibiting Abl oncoprotein transformation. Forty per cent of v-Abltransformed pre-B lymphocyte clones isolated in vitro express mutant forms of p53 (Thome et al., 1997) , and loss of p53 function has been suggested to play an important role during the blast phase of CML induced by Bcr ± Abl (Prokocimer and Rotter, 1994; Skorski et al., 1996) . We show that v-Abl transformation of MEFs is blocked by p53 and p19ARF, and can be facilitated by loss of these gene products in mutant cells. Our results are consistent with these previous ®ndings and provide further evidence for the importance of the p19ARF-p53 pathway in v-Abl dependent transformation.
Growth suppression pathways
The development of cancer is often associated with the inactivation of two major growth suppression pathways mediated by Rb and p53. Loss of Rb function results in elevated activity of E2F transcription factors and uncontrolled cell growth, but elevated E2F activity evokes p53-dependent cell cycle arrest and/or apoptosis. v-Abl is able to inactivate Rb through the Ras pathway (Zou et al., 1997) . However, induction of the Ras pathway and inactivation of Rb by v-Abl is not sucient to transform primary ®broblasts; instead, vAbl causes cell cycle arrest in primary ®broblasts. Other oncoproteins have been shown to exhibit similar con¯icting activities. For example, Ras transforms immortal ®broblasts, but not primary ®broblasts (Newbold and Overell, 1983) . Instead, Ras induces cell cycle arrest in primary ®broblasts associated with accumulation of p53, p16INK4a and p19ARF (Palmero et al., 1998; Serrano et al., 1997) . In culture, Ras only transforms primary cells in cooperation with other oncogene products such as Myc and E1A. Interestingly, Myc and E1A elicit p53-dependent apoptosis in primary cells (de Stanchina et al., 1998; Zindy et al., 1998) , and it has been speculated that Myc and E1A cooperate with Ras at least partially through enforcing a selection of cells with a dismantled p53 checkpoint (Prives, 1998) .
Expression of v-Abl in wild-type primary MEFs induced cell cycle arrest associated with elevated levels of p19ARF, p53 and p21 Cip . Signi®cantly, p53 7/7 and p19ARF 7/7 MEFs are resistant to v-Abl induced cell cycle arrest, suggesting that p53 and p19ARF are required for the growth inhibitory eect of v-Abl in primary ®broblasts. Most v-Abl-expressing wild-type MEFs adopted an extended and¯at morphology, similar to cells in senescence. Notably, active forms of Ras, Raf and MEK all induce premature senescence in primary ®broblasts (Lin et al., 1998; Serrano et al., 1997; Zhu et al., 1998) . Premature senescence might represent a fail-safe mechanism for normal cells to defend against abnormal mitogenic signals.
The pathways from v-Abl to p53
Our data show that the p53 pathway is actively triggered by v-Abl, which in turn counteracts v-Abl transforming activity. How does v-Abl trigger the p53 pathway? A number of studies suggest that p19ARF and p53 act in the same signal transduction pathway and that p19ARF functions upstream of p53; establishment of immortal cell lines from primary MEFs is usually accompanied by either p19ARF or p53 loss of function, but rarely both, and p53
7/7
MEFs are resistant to cell cycle arrest induced by overexpression of p19ARF (de Stanchina et al., 1998; Kamijo et al., 1997; Zindy et al., 1998) . p19ARF activates p53 both by physically interacting with MDM2 to block MDM2-induced p53 degradation, and by directly interacting with p53 Pomerantz et al., 1998; Zhang et al., 1998) . We suggest that p19ARF mediates v-Abl dependent p53 activation. This idea is consistent with the observation that the expression levels of p19ARF were increased in AMuLV infected wild-type MEFs and v-Abl transformed p53 7/7 MEFs, and it is further supported by the ®nding that v-Abl failed to elevate p53 protein levels in p19ARF 7/7 MEFs. How does v-Abl stimulate p19ARF expression? Ectopic expression of Ras, Raf, MEK, myc, E1A, and E2F-1 in primary cells all result in the upregulation of p19ARF expression (Bates et al., 1998; de Stanchina et al., 1998; Lin et al., 1998; Palmero et al., 1998; Zhu et al., 1998; Zindy et al., 1998) . Unlike p53, which is mainly regulated by protein stabilization and posttranscription modi®cation, p19ARF seems to be largely regulated at the transcriptional level. Analysis of the promoter of human ARF reveals a potential E2F binding site, which can be eciently activated by E2F in cotransfection assays (Bates et al., 1998) . v-Abl induces the RasRaf-MAP kinase pathway, and also the activity of E2F and Myc (Rael et al., 1996; Raitano et al., 1995; Renshaw et al., 1996; Wong et al., 1995; Zou et al., 1997) , and thus it is likely that v-Abl induces the p19ARF-p53 pathway through Ras, Raf, myc and E2F.
Although the induction of p53 by v-Abl in primary MEFs is p19ARF-dependent, the wild-type c-Abl protein induces p53 in NIH3T3 cells which are p19ARF null. c-Abl is known to bind to p53 and induces the stabilization of p53 through a proline-rich region in its C-terminal part (Goga et al., 1995; Yuan et al., 1996) . It is conceivable that v-Abl also interacts with and directly stabilizes p53. However, direct activation of p53 by v-Abl is not likely since v-Ablinduced p53 induction is p19ARF-dependent in primary MEFs.
Disruption of p53 or p19ARF and v-Abl transformation
The fact that many Abl tumors show loss of p53 suggests that p53 7/7 cells have a growth advantage over normal cells. Our study provides a possible explanation for this phenomenon. Excessive mitogenic signals induced by vAbl trigger the p19ARF/p53-dependent growth inhibitory pathway. Rosenberg et al. show that primary AMuLV lymphoid transformants from ARF 7/7 or p53
mice can bypass apoptotic crisis and become established very rapidly, suggesting that p53 and p19ARF restrict transformation of pre-B cells by v-Abl (Radfar et al., 1998; Unnikrishnan et al., 1999) . Disruption of p53 function facilitates v-Abl transformation not only in vitro, but also in vivo. We ®nd that p53 7/7 mice injected with AMuLV developed pre-B cell tumors with a signi®cantly shorter latency as compared with their wild-type littermates (unpublished data).
The toxicity of v-Abl in the immortal ®broblasts
The C-terminal region of v-Abl triggers certain critical signaling pathways and is required for transforming primary pre-B lymphocytes in vivo (Rosenberg et al., 1980) . However, in immortal ®broblasts, the Cterminal region of v-Abl is associated with the v-Abl growth inhibitory eect. Interestingly, this C-terminal region can bind to p53, and is responsible for c-Ablmediated p53 induction and cell cycle arrest (Goga et al., 1995; Yuan et al., 1996) . The transformation activity of v-Abl depends on cell context. Of two NIH3T3 populations, v-Abl only transforms the permissive class of cells, and causes cell cycle arrest in the non-permissive class of cells (Renshaw et al., 1992) . Thus v-Abl toxicity in NIH3T3 cells might largely result from v-Abl-induced cell cycle arrest. Cell fusion experiments indicate that the permissive phenotype is dominant (Renshaw et al., 1992) . In contrast to 1A4 non-permissive cells, 4A2 permissive cells fail to induce p21
Cip expression in response to DNA damage, indicating a defective p53 function . These observations suggest that p53 might impede v-Abl in immortal ®broblasts. To examine this possibility we disrupted p53 function in 1A4 non-permissive cells and tested their susceptibility to v-Abl toxicity. The counterselection assay indicated that v-Abl was still toxic to 1A4-E6 cells, suggesting that v-Abl exerts its toxicity in the non-permissive cells through a largely p53-independent pathway. Our study suggests that c-Abl and v-Abl induce cell cycle arrest in NIH3T3 cells through distinct mechanisms. An unknown signal transduction pathway associated with the C-terminal region of v-Abl may be responsible for the toxicity of v-Abl. Notably, it has been shown that v-Abl induces cell cycle arrest in the non-permissive cells by repressing cyclin A expression (Chen et al., 1996) . The mechanism by which v-Abl represses cyclin A expression is not understood.
Taken together, our results and those of others support the notion that v-Abl simultaneously stimulates two antagonistic sets of signals in primary cells. On one hand, v-Abl initiates strong mitogenic signals, which promote cell growth and transformation. On the other hand, v-Abl signaling can trigger the p19ARF-p53 pathway. p53 then induces the expression of p21 Cip and other downstream eectors, causing cell cycle arrest and possibly also apoptosis. Cells without normal ARF or p53 function lose this inhibitory mechanism, allowing growth promoting signals to predominate. On another level, v-Abl also exerts its toxicity in immortal ®broblasts through the C-terminal region of v-Abl via an ARF/p53-independent pathway. The nature of this toxicity requires further study.
Materials and methods
Cell culture
Early passage cultures of p53 +/+ and p53 7/7 MEFs were obtained from Tyler Jacks (Massachusetts Institute of Technology) (Jacks et al., 1994) . We also prepared additional p53 +/+ and p53 7/7 MEFs from littermates of a cross between p53 +/7 heterozygous mice (Jacks et al., 1994) . MEFs from 13.5-day-old embryos were explanted and maintained on a 3T9 protocol based on a strategy of Todaro and Green (1963) . Early passage cultures of p19ARF +/+ and p19ARF 7/7 cells were obtained from Charles Sherr (St. Jude Children's Hospital) (Kamijo et al., 1997) . The cells were propagated in Dulbecco's Modi®ed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 55 mM b-mercaptoethanol and penicillin/streptomycin. The wild-type MEFs obtained from Tyler Jacks Laboratory, Charles Sherr Laboratory and wild-type MEFs generated in our own laboratory behave indistinguishably in our assays. Cells were maintained on a de®ned schedule (9610 5 cells per 60 mm diameter plate and passaged every 3 days). Phoenix packaging cell line was obtained from Gary Nolan (Stanford University). 1A4 and 4A2 cells were obtained from Jean Y Wang (University of California at San Diego, CA, USA) (Renshaw et al., 1992) .
Plasmid and virus
The retroviral vector pGDN containing the neomycin resistance gene under the control of the herpes simplex thymidine kinase promoter, and pGD-v-Abl carrying the v-Abl p160 gene under the control of the long terminal repeat of the murine sarcoma virus, were obtained from David Baltimore (California Institute of Technology, CA, USA) (Pear et al., 1993) . pGD-v-AblPuro was generated by replacing the neomycin resistance gene cassette of pGD-v-Abl with the puromycin resistance gene cassette from pBabePuro. A retrovirus expressing the HPV16 E6 gene and a neomycin resistance gene was obtained from Denise Galloway (Fred Hutchinson Cancer Research Center) (Halbert et al., 1991) . E6-expressing virus was collected from a stable producer cell line and used without dilution to infect MEFs. After 16 h the cultures were exposed to A-MuLV and then plated in agar for a colony formation assay.
Retroviral mediated gene-transfer
The ecotropic Phoenix packaging cells (5610 6 ) were plated in 100 mm dishes 24 h before transfection. Five hundred ml of HEPES buered saline solution (pH 7.05) was added to an equal volume of DNA/CaCl 2 solution by bubbling, and the resulting solution was immediately added to cells. Cells were returned to a 378C incubator (5% CO 2 ), and refed with fresh medium 16 h after transfection. Twenty mg of DNA was used for the transfection of one 100 mm dish. Virus-containing medium was collected and ®ltered (0.45 mM ®lter, Millipore) 40 h later and supplemented with 4 mg/ml polybrene (Sigma) and 20 mM HEPES. Medium was collected again after an additional 12 h incubation and two collections were pooled together. MEFs were plated at 40% con¯uence, incubated with virus containing medium for 12 h at 378C. The infection procedure was repeated. Twenty-four hours after infection, cells were split and subjected to puromycin selection (4 mg/ml) for 7 days.
Cell cycle analysis
After selection, MEFs were plated on coverslips in 6-well plates. Twenty-four hours later, 5-bromo-2-deoxyuridine (BrdU) at 20 mM was added to the medium. Eighteen hours after the addition of BrdU, cells were ®xed and BrdU incorporation was detected with the BrdU Labeling and Detection Kit I (Boehringer Mannheim). Brie¯y, coverslips were washed with PBS and ®xed with 100% methanol for 15 min at 7208C. Coverslips were rinsed several times, and incubated with antiBrdU antibody solution, which contains nucleases for DNA denaturation, for 30 min at 378C. Coverslips were then rinsed and incubated with¯uorescein-conjugated anti-mouse IgG antibodies for 30 min at 378C. Cells were counterstained with DAPI to identify all nuclei. Finally, cells were examined with an immuno¯uorescence microscope (Nikon). For each sample, more than 300 cells were scored for BrdU incorporation. Each experiment was performed three times.
Immunoblot analysis
Cells were washed with ice-cold PBS and lysed in RIPA buer (10 mM sodium phosphate, pH 7.4, 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM NaF, 10 mM b-glycerophosphate, 1 mM phenylmethylsulfonyl uoride, 10 mg/ml of leupeptin and 10 mg/ml of aprotinin) by rocking at 48C for 30 min. Cell lysates were clari®ed by centrifuging for 20 min at 13 000 r.p.m. Whole cell lysates were resolved by SDS-polyacrylamide gel electrophoresis (SDS ± PAGE), transferred to a nitrocellulose membrane (Schleicher & Schuell), probed with anti-Abl (K-12) antibodies (Santa Cruz), anti-p53 (Ab 7) antibodies (Oncogene Science), or anti-p21
Cip antibodies (Santa Cruz), and then incubated with horseradish peroxidase-conjugated secondary antibodies (Amersham). Antibody binding was detected with an enhanced chemiluminescence (ECL) kit (Amersham).
Soft agar assay
5610
5 MEFs were plated 24 h before infection. Cells were infected with 2 ml of A-MuLV or Mo-MuLV for 4 h. Twenty-four hours after infection, cells were trypsinized, added to DMEM medium containing 0.3% agar and 20% fetal bovine serum, and plated onto 60 mm diameter plates with 0.5% agar. Colonies were counted 2 weeks after infection. Some colonies were picked up from soft agar and expanded in liquid culture.
Ribonuclease protection assay
Total RNA was prepared from Mo-MuLV or A-MuLVinfected wild-type MEFs using RNAzol B isolation method (TEL-TEST). The amount of RNA in each sample was determined both by OD 260 and by ethidium bromide staining of agarose gels. An antisense probe corresponding to the nucleotide 325 ± 713 of p19ARF cDNA was prepared by in vitro transcription reactions (Ambion). A b-Actin antisense probe was also prepared by in vitro transcription reactions (Ambion). The RNA probes were puri®ed by electrophoresis on a 5% polyacrylamide/urea gel. Total RNA (10 mg) from each sample was used to protect the probes from RNase A plus T1 digestion for the RPA III ribonuclease protection assay (Ambion). The digestion products were resolved on a 5% polyacrylamide/urea gel and detected by autoradiography.
Northern blot
Total RNA was prepared by lysing cells with 25 mM sodium citrate, pH 7.0, 4 M guanidium thiocyanate, 0.5% N-lauryl sarcosine, 100 mM mercaptoethanol. Lysates were pelleted through a 5.7 M CsCl cushion by centrifuging for 12 h at 36 000 r.p.m. in a SW55 rotor. Twenty mg of total RNA per sample were resuspended in 0.56formaldehyde gel-running buer (10 mM MOPS, pH 7.0, 4 mM sodium acetate, 0.5 mM EDTA), 17.5% formaldehyde, 50% formamide, incubated at 658C for 15 min, chilled on ice, and tap spun at 48C. Two ml of formaldehyde gel-loading buer (50% glycerol, 1 mM EDTA, 0.25% bromphenol blue, 0.25% xylene cyanol) were added to each sample, and RNA was separated on a formaldehyde-agarose gel (1% agarose, 16formaldehyde gel-running buer, 2.2 M formaldehyde). RNA was transferred to Hybond-N nylon membranes (Amersham Lifescience) by capillary action using 206SSC (3 M NaCl, 0.3 M sodium citrate). RNA was ®xed to the membrane by crosslinking and hybridized with radiolabeled probes at 658C in 1.56SSCPE (0.18 M NaCl, 22.5 mM Na citrate, 15 mM KH 2 PO 4 , 1.5 mM EDTA), 10% polyethylene glycol, 7% SDS, 0.1 mg/ml salmon sperm DNA for at least 12 h. Filters were washed twice for 5 min each in 26SSC, 0.1% SDS, twice for 10 min each in 0.26SSC, 0.1% SDS, and once for 15 min in 0.16SSC, 0.1% SDS. All washes were carried out at 658C. Filters were stripped by washing at 1008C in 0.1% SDS. Radiolabeled probes with a speci®c activity of 45610 7 were generated by random priming gelisolated DNA fragments of p19ARF and GAPDH probes according to the instructions of the manufacturer (United States Biochemical, Cleveland, OH, USA).
Counterselection assay
1A4 and 4A2 cells transduced with pGDN or E6 virus were plated onto 60 mm plates 24 h before transfection. Cells were transfected with 6 mg of PGD-v-AblPuro, or 5.5 mg of pGDN plus 0.5 mg of pBabePuro with a standard calcium phosphate transfection method. Forty-eight hours after transfection, cells were split and selected in medium containing 10 mg/ml of puromycin. Ten days after selection, the colonies were counted.
Focus forming assay
1A4 and 4A2 cells transduced with pGDN or E6 virus were infected with dierent dilutions of pGDN or pGD-v-Abl virus. Thirty-six hours after infection, cells were starved in DMEM medium supplemented with 4% bovine calf serum. After a 2-week incubation, transformed foci were counted. The titer of virus was determined as the number of focusforming units (f.f.u.) per milliliter for A-MuLV.
